Australian medical device company, Oventus Medical Ltd. (ASX:OVN) has today released its Appendix 4C - Quarterly cash flow report for the period ended 30 June 2017.
Last year some of the Best Boards in their sectors were AMC, CBA, MFG, BXB and SYD, but who will be the Best Boards for 2017? Fund managers are able to vote now to determine this year's winners. Voting will be closing down Friday 28 July.
Oventus Medical Limited (ASX:OVN) announced a share purchase plan to the market on 22 June 2017. Oventus wishes to advise that the closing date for the SPP will be extended from Wednesday 19 July 2017 to Monday 31 July 2017.
Australian medical device company, Oventus Medical Ltd. (ASX:OVN) has received FDA 510k clearance for its O2Vent W device, an oral appliance intended to reduce or alleviate snoring and mild to moderate obstructive sleep apnoea.
Boardroom.media and East Coles recently entered a partnership affording Boardroom.media access to East Coles data. As a result of this partnership Boardroom.media will act as a media partner for the annual East Coles Awards Night.
Oventus Medical Ltd (ASX:OVN) announced a share purchase plan to the market on 22 June 2017. The record date to be registered as a shareholder for participation in the SPP is Wednesday, 21 June 2017.
Oventus Medical Limited (ASX:OVN) announces that it has completed a first tranche placement of approximately 18 million shares to institutional and sophisticated investors at an issue price of $0.36 per share to raise approximately $6.5 million.
Oventus Medical Ltd (ASX:OVN) is pleased to announce it has entered into a world-wide distribution agreement with Hong Kong based Modern Dental Group (HKG:3600). This is in addition to the recent announcement of the co-manufacturing agreement between Oventus and Modern Dental.
The 2017 East Coles / Transplant Australia Corporate Performance Awards Night will be held at the Ivy Ballroom on Thursday, 21 September. The incredibly talented electric violin artist Jane Cho will be performing on the night along with other entertainment.
(NetworkNewsWire) With more than a century of combined experience spanning the gamut from pancreas/GI tract issues in hepato-gastroenterology and infectious disease to the development of novel non-systemic (localized) therapeutic biologics and proteomics (protein engineering), the AzurRx BioPharma, Inc. (NASDAQ:AZRX) core science team is the real strength behind the company's developing portfolio of recombinant therapies.
Banking & Finance
- Chapmans Limited (ASX:CHP) Extension of Closing Date of Rights Issue
- iSignthis Ltd (ASX:ISX) Appendix 4C - Quarterly
- iSignthis Ltd (ASX:ISX) Tradefinancial Transacting via ISXPay Australia
Oil Gas & Energy
- Genex Power Ltd (ASX:GNX) Kidston Solar Phase One 50MW Update
- Cobalt Blue Holdings Limited (ASX:COB) Quarterly Activities and Cash Flow Reports September 2017
- Liquefied Natural Gas Ltd (ASX:LNG) 2017 Annual Report - Shareholders' Version